Oral Micronized Progesterone in Adolescents (12, 17): Safety, Evidence, and Monitoring

Why There Is No Pediatric FDA Label

The FDA approved Prometrium in 1998 for two adult indications: secondary amenorrhea and prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens 2. Neither indication applies to adolescents, and the manufacturer never submitted a pediatric supplemental application.

This regulatory gap is common across reproductive endocrinology. The Endocrine Society's 2017 guideline on gender-dysphoria management acknowledged the lack of controlled pediatric progesterone data while still permitting clinician judgment for off-label use when benefit outweighs risk [3]. Dr. Wylie Hembree, the guideline's lead author, stated: "Clinicians treating adolescents must rely on extrapolation from adult pharmacology, developmental physiology, and careful longitudinal follow-up."

The absence of a label does not mean the drug is unsafe in younger patients. It means the formal safety dossier that the FDA requires (Phase III trials with pediatric endpoints) has never been assembled. Drugs like spironolactone and metformin follow the same pattern: widely used in adolescents without a pediatric-specific approval 4.

What the Adult Evidence Tells Us

The PEPI trial (Postmenopausal Estrogen/Progestin Interventions), published in JAMA in 1995, remains the largest randomized comparison of OMP against synthetic progestins 1. In 875 postmenopausal women followed for three years, micronized progesterone 200 mg/day (cyclic, 12 days/month) provided endometrial protection equivalent to MPA 10 mg/day. OMP preserved the HDL cholesterol benefit of estrogen therapy while MPA blunted it by approximately 15%.

A 2012 meta-analysis in Climacteric (N=28,098 across 5 cohort studies) found that OMP carried no increased breast cancer risk over a median 8.1-year follow-up, whereas synthetic progestins increased risk by 1.69-fold 5. These findings shaped the preference for OMP over MPA in adult HRT.

How much of this transfers to a 14-year-old? The pharmacokinetic pathway is identical. OMP is absorbed in the small intestine, undergoes hepatic first-pass metabolism to pregnanolone and allopregnanolone, and has a half-life of 16 to 18 hours regardless of age 2. No published pharmacokinetic study has identified age-dependent clearance differences in patients with mature hepatic function (generally established by Tanner stage 3 to 4). The metabolic machinery is the same. The unknowns are developmental.

Off-Label Uses in Adolescents

Clinicians prescribe OMP to adolescents for a narrow set of indications, each with its own risk-benefit calculus.

Abnormal uterine bleeding (AUB). Anovulatory cycles account for roughly 75% of AUB in the first two years after menarche 6. ACOG Committee Opinion 785 (2019) lists cyclic progestin therapy as a first-line option, with OMP 200 mg nightly for 10 to 12 days per cycle as one regimen 7. This is the most evidence-supported adolescent application.

Gender-affirming hormone therapy. The Endocrine Society guideline 3 and the WPATH Standards of Care (Version 8) reference progesterone as an adjunct in feminizing regimens, sometimes started in mid-to-late adolescence to promote breast ductal development. Data on efficacy for this specific endpoint remain preliminary.

Hypothalamic amenorrhea recovery. Adolescents recovering from functional hypothalamic amenorrhea (often associated with low energy availability) may receive cyclic OMP to induce withdrawal bleeds, confirming adequate endogenous estrogen levels. The American Academy of Pediatrics has endorsed this diagnostic use while cautioning that it should not replace addressing the underlying energy deficit [8].

Safety Signals Specific to Adolescent Physiology

Three developmental domains require attention when prescribing OMP to patients aged 12 to 17.

Bone accrual. Adolescence is the critical window for peak bone mass acquisition, with roughly 40% of lifetime bone mineral density accrued between ages 12 and 18 9. Progesterone's effect on bone in adolescents is not well characterized. In adult premenopausal women, Dr. Jerilynn Prior's research at the University of British Columbia showed that cyclic OMP 300 mg/day for 10 days/cycle increased spinal bone formation markers over 12 months compared to placebo 10. Prior noted: "Progesterone appears to stimulate osteoblast-mediated bone formation, acting through a distinct mechanism from estrogen's anti-resorptive effect." Whether this translates to net benefit or interference with the adolescent growth plate remains unstudied. Baseline DXA and annual follow-up are prudent for any adolescent on continuous OMP beyond six months.

Neuropsychiatric effects. OMP's primary metabolite, allopregnanolone, is a potent positive allosteric modulator of GABA-A receptors 11. This produces the sedation that makes bedtime dosing standard. In adults, this property is generally benign. The adolescent brain, however, is undergoing prefrontal cortex maturation and exhibits heightened sensitivity to GABAergic modulation 12. Clinicians should screen for excessive daytime somnolence, mood changes, and depressive symptoms at each visit. The PHQ-A (Patient Health Questionnaire for Adolescents) is a validated, brief screening instrument for this purpose.

Hepatic considerations. OMP undergoes extensive first-pass hepatic metabolism. The FDA label lists a caution for patients with hepatic impairment 2. Adolescents with obesity-associated MASLD (metabolic dysfunction-associated steatotic liver disease), a rising concern in this age group, may have altered drug clearance. Liver function testing before initiation and at 3 months is a reasonable precaution, though no formal guideline mandates it.

Dosing Protocols for Adolescent Patients

No consensus pediatric dosing guideline exists. The protocols below reflect published expert opinion and institutional practice patterns rather than randomized trial evidence.

For cyclic menstrual regulation, the most common approach is OMP 200 mg orally at bedtime on cycle days 14 through 25 (or for 10 to 12 days starting 14 days after the last menstrual period onset). This mirrors ACOG's adult AUB recommendation 7 scaled to adolescent use. Some clinicians start at 100 mg for the first cycle to assess tolerability, then increase to 200 mg.

For continuous use (gender-affirming care or endometrial protection alongside estrogen therapy), 100 mg nightly is the typical starting dose, with escalation to 200 mg based on clinical response.

All oral OMP capsules should be taken at bedtime to minimize the sedative effect of allopregnanolone. Taking the capsule with a small amount of food (not a full meal) improves absorption. The Prometrium label reports that peak serum progesterone levels increase from 17.5 ng/mL fasted to 25.4 ng/mL fed (a 45% increase), which may affect both efficacy and side effects 2.

The Peanut Oil Problem

Prometrium brand capsules use peanut oil as a suspension vehicle. The FDA label carries a contraindication for patients with known peanut allergy 2. Among U.S. adolescents, peanut allergy prevalence is approximately 2.2% 13.

For these patients, compounding pharmacies can prepare OMP capsules using olive oil or a vegetable-oil base. Some generic manufacturers have also moved to non-peanut oil formulations. Clinicians should verify the inactive ingredient list of the dispensed product. Vaginal administration of oral OMP capsules (an off-label route used in adults for luteal support in fertility treatment) bypasses first-pass metabolism but introduces different absorption kinetics and is not standard practice in adolescents.

Monitoring Framework

A structured follow-up plan reduces risk in any off-label pediatric prescription. The following schedule reflects consensus from pediatric endocrinology and adolescent gynecology practice.

Before starting OMP:

• Confirm the clinical indication and document it
• Screen for peanut allergy
• Obtain baseline liver function (ALT, AST) if the patient has obesity or known MASLD
• Assess mood with PHQ-A
• Consider baseline DXA if continuous use beyond 6 months is anticipated
• Obtain informed consent from patient and guardian, documenting the off-label nature

At 1 month:

• Assess tolerability (sedation, headache, GI symptoms)
• Review menstrual diary or bleeding pattern
• Re-screen mood

At 3 months and every 3 months thereafter:

• PHQ-A or equivalent mood screen
• Menstrual pattern review
• Liver function if baseline was abnormal or if the patient is on concurrent hepatotoxic medication
• Growth velocity check (for patients under 16)

Annually:

• DXA if on continuous therapy
• Reassess whether the indication still applies (anovulatory bleeding often resolves within 2 to 3 years of menarche as the HPO axis matures)

Comparing OMP to Synthetic Progestins in Adolescents

When clinicians choose a progestin for an adolescent, the decision often comes down to OMP versus medroxyprogesterone acetate (MPA) or norethindrone acetate (NETA).

OMP offers three advantages suggested by adult data: a neutral-to-favorable lipid effect (PEPI trial 1), no demonstrated increase in breast cancer risk over 8 years of follow-up 5, and a sedative profile that may benefit patients with concurrent insomnia. Its disadvantages include the peanut oil concern, the need for daily dosing (no depot formulation exists), and lower progestational potency per milligram compared to synthetic alternatives.

MPA is available as a depot injection (Depo-Provera, 150 mg IM every 12 weeks), which solves adherence problems but introduces bone density loss that the FDA black-boxed in 2004 [14]. The label recommends limiting Depo-Provera use to two years in adolescents unless other methods are inadequate. This bone concern does not apply to OMP based on available evidence.

NETA is the progestin component of many combined oral contraceptive pills and is well studied in adolescents for contraceptive purposes, but less so as a standalone progestin for AUB or endometrial protection.

When to Avoid OMP in Adolescents

Absolute contraindications mirror the adult label: known or suspected pregnancy, active thrombophlebitis or thromboembolic disorders, known hypersensitivity to progesterone or peanut (for Prometrium brand), and undiagnosed vaginal bleeding that has not been evaluated 2.

Relative contraindications in adolescents include severe depression (allopregnanolone's GABAergic activity could worsen symptoms in susceptible individuals), active liver disease with transaminases exceeding 3 times the upper limit of normal, and concurrent use of strong CYP3A4 inducers (carbamazepine, phenytoin, rifampin) that may reduce OMP levels below therapeutic thresholds.

Clinicians should also reconsider OMP if an adolescent patient reports persistent next-day drowsiness that interferes with school performance, a practical concern that adult dosing guidance often overlooks.